FindTrial
Sign In

Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients

Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients: a Multicenter Retrospective Study in China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05749445
Enrollment
200
Registered
2023-03-01
Start date
2022-12-15
Completion date
2023-04-30
Last updated
2023-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hospitalized Patients

Brief summary

The primary objective of the study was to assess the appropriateness of antiviral therapy with nirmatrelvir-ritonavir in hospitalized patients.

Interventions

DRUGNirmatrelvir-Ritonavir

Nirmatrelvir-Ritonavir

Sponsors

Hangzhou Cancer Hospital
CollaboratorOTHER
First People's Hospital of Lin'an District
CollaboratorUNKNOWN
First People's Hospital of Yuhang District
CollaboratorUNKNOWN
First People's Hospital of Hangzhou
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* hospitalized patients receiving at least one dose nirmatrelvir-ritonavir

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
The prevalence of inappropriate use of nirmatrelvir-ritonavirbaselineFour aspects were evaluated to identify the rationality of prescribing NMVr, including indication, administration (dose, timing, and duration), contraindications, and drug-drug interactions.

Countries

China

Contacts

Primary ContactChangcheng Shi
cpushicc@163.com86-13967157030

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026